Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

OBJECTIVE: Sodium-glucose cotransporter-2 inhibitors have been identified profound renal/cardiac protective effects in different diseases. Here, we assessed the safety and efficacy of dapagliflozin among adult patients with systemic lupus erythematosus (SLE). METHODS: We conducted a single-arm, open...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huijing, Li, Ting, Sun, Fangfang, Liu, Zhe, Zhang, Danting, Teng, Xiangyu, Morel, Laurence, Wang, Xiaodong, Ye, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615980/
https://www.ncbi.nlm.nih.gov/pubmed/36288823
http://dx.doi.org/10.1136/rmdopen-2022-002686

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615980/
https://www.ncbi.nlm.nih.gov/pubmed/36288823
http://dx.doi.org/10.1136/rmdopen-2022-002686

Ejemplares similares